Mar 06, 2023 / 02:10PM GMT
Max Masucci - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
We have Max Krakowiak, CFO, PerkinElmer. Thank you to both of you for being here.
Just as a quick reminder, we made an out-of-consensus upgrade call on Perkin in early January. There have been 2 additional upgrade sense. Our view is that the company's recent acquisitions, particularly BioLegend and its forthcoming divestitures make the go-forward Perkin much different from the Legacy Perkin that many investors are familiar with. So with that said, our questions will be focused on the topics that we uncovered during our process of upgrading the stock.
So before we jump into some questions that are specific to the continuing operations, I just want to hit a few big picture questions.
Questions and Answers:
Max Masucci - Cowen and Company, LLC, Research Division - MD & Senior Research AnalystJust latest expectations for when the planned business divestiture will close. Are there any risk factors that we should be aware of in terms of